Back to Freepaper Session

Trabeculectomy with collagen matrix implantation versus trabeculectomy with Mitomycin C application for treatment of primary congenital glaucoma

Session Details

Session Title: Special Cases

Session Date/Time: Friday 14/02/2014 | 08:30-10:00

Paper Time: 09:38

Venue: Kosovel Hall (Level -2)

First Author: : Mohammed IqbalHafez Ahmed EGYPT

Co Author(s): :                  

Abstract Details

Purpose:

To verify the safety and efficacy of collagen maytix implant (Ologen (OLO) implant) as adjuvant compared with low-dosage mitomycin-C (MMC) in trabeculectomy for surgical treatment of primary congenital glaucoma.

Setting:

Ophthalmology department, Sohag University hospital, Egypt

Methods:

This was a prospective randomized clinical trial with a 6-month follow-up. Fifteen patients with primary congenital glaucoma were assigned to trabeculectomy with MMC or collagen matrix implant (OLO implant). Primary outcome includes target IOP at ≤ 21, ≤ 17, and ≤15mmHg. Secondary outcomes include clinical bleb evaluation, number of glaucoma medications; and frequency of postoperative adjunctive procedures and complications.

Results:

The mean preoperative IOP was 35 (±5.3) in MMC and 32 (±6.2) in OLO eyes, without statistical significance. One-day postoperatively, the IOP dropped to 9.2 (±3.5) and 5.2 (±5.5) mmHg, respectively (P=0.009). The IOP reduction was significant at end point in all groups (P=0.01), with a mean IOP of 16.0 (±2.9) and 16.5 (±2.1) mmHg in MMC and OLO, respectively. The bleb was well formed in OLO group more than MMC one (P<0.05). No adverse reaction to OLO was noted.

Conclusions:

the results of this study suggested that the collagen matrix implant could be a new, safe, and more effective alternative to MMC with fewer complications. Due to our small sample size, which limits the statistical comparison between the groups, further larger randomized trials are required to investigate the long term efficacy and safety of this new device. FINANCIAL INTEREST: NONE